<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609166</url>
  </required_header>
  <id_info>
    <org_study_id>IIB-ALO-2010-02</org_study_id>
    <secondary_id>2010-022095-31</secondary_id>
    <nct_id>NCT01609166</nct_id>
  </id_info>
  <brief_title>Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome</brief_title>
  <official_title>Placebo-controlled Trial to Determine the Effectiveness of a 3% Allopurinol-base Topical Agent for Prevention of Capecitabine-induced Hand-foot Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hand-foot syndrome (HFS) is a dose-limiting toxicity of capecitabine for which no effective
      preventative treatment has been definitively demonstrated. This trial is conducted on the
      basis of preliminary data that a 3% allopurinol-based topical agent may prevent HFS.

      A randomized, double-blind phase III trial will evaluate 40 patients receiving their first
      ever cycle of capecitabine at a dose of either 2,000 or 2,500 mg/m2 per day for 14 days.
      Patients will be randomly assigned to a 3% allopurinol versus a placebo cream, which will be
      applied to the hands and feet twice per day for 6 months after the start of capecitabine.
      Patients will be examined every month and the investigators will take some photographs of
      hands and feet. HFS toxicity grade (Common Terminology Criteria for Adverse Events
      [CTCAE]v3.0) will be also collected at baseline and at the end of each cycle. The primary end
      point is the incidence of moderate/severe HFS symptoms at the end of capecitabine treatment ,
      based on the patient-reported dermatological exploration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the signs of hand-foot syndrome</measure>
    <time_frame>At 1-2-3-4-5-6 months</time_frame>
    <description>Erythema, descamation, vesiculation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the symptoms of hand-foot syndrome</measure>
    <time_frame>At 1-2-3-4-5-6 months</time_frame>
    <description>Burning, prurigo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hand-foot Syndrome</condition>
  <arm_group>
    <arm_group_label>Allopurinol 3% cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allopurinol 3% cream in one side of the body</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream in the other side of the body</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Allopurinol 3% cream application in one side of the body, twice a day for 6 months</description>
    <arm_group_label>Allopurinol 3% cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo cream application in the other side of the body, twice a day for 6 months</description>
    <arm_group_label>Placebo cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18years-old,that initiate treatment with oral capecitabine,
             without signs of hand-feet syndrome toxicity.

          -  Free acceptance to participate part in this clinical trial, with signature of the form
             of informed assent approved for the study, writing of the volunteer.

        Exclusion Criteria:

          -  Age lower than 18 years

          -  Precedents of allergy, idiosyncrasy or hypersensitivity to the medicament.

          -  Denial of the patient to sign the informed assent.

          -  Any disorder or current / previous treatment that, in the opinion of the investigator,
             incapacitates the patient to take part in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hand-foot Syndrome</keyword>
  <keyword>capecitabine</keyword>
  <keyword>allopurinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hand-Foot Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Allopurinol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

